| Title | Authors | Journal and date | |
| 1 | Contributions to the Study of Marine Products. XXXII. The Nucleosides of Sponges. I. | Werner Bergmann and Robert J. Feeney | J. Org. Chem. 16:981, 1951 |
| 2 | The Isolation of a New Thymine Pentoside from Sponges | Bergmann and Feeney | J Am Chem Soc, 72, 2809, 1950 |
| 3 | Contributions to the Study of Marine Products. XXXII. The Nucleosides of Sponges. III. Spongothymidine and Spongouridine. | Werner Bergmann and Derek C. Burke | J. Org. Chem. 20:1501, 1955 |
| 4 | Sponges, Cancer, Cellular Aging | Seymour S. Cohen | Perspectives in Biology and Medicine, Winter 1963 |
| 5 | Antitumor Activity of 1-beta-D-Arabinofuranosylcytosine Hydrochloride. | John s. Evans, Elizabeth A. Musser, Gordon D. Mengel, Karin R. Forsblad and James H. Hunter | Proceedings of the Society for Experimental Biology and Medicine, 106, No. 2: 350-353, 1961 |
| 6 | The induction of thymine deficiency and the effects of thymine and thymidine analogs in E. coli. | Cohen, Seymour S.; Barner, Hazel D. | Journal of Bacteriology, 1956, 71, 588-97. |
| 7 | The activity of nucleoside phosphorylase on 1-beta-D-arabinosyluracil within E. coli. | Tono, Henrique; Cohen, Seymour S. | Journal of Biological Chemistry, 1962, 237, 1271-82. |
| 8 | Inhibition of mammalian DNA polymerase by the 5’-triphosphate of 1-beta-D-arabinofuranosylcytosine and the 5’-triphosphate of 9-beta-D-arabinofuranosyladenine. | Furth, John J., Cohen, Seymour S. | Cancer Research, 1968, 28 (10), 2061-7. |
| 9 | The lethality of aranucleotides. | Cohen, Seymour S. | Medical Biology, 1976, 54 (5), 299-326. |
| 10 | The mode of action of 5-fluorouracil and its derivatives. | Cohen, SS, Flaks, JG, Barner HD, Loeb MR, and Lichtenstein J. | PNAS, US, 44: 1004-12, 1958. |
| 11 | Cytosine arabinoside (NSC-63878) in acute leukemia in children. *This is an important and often-cited article. | Howard, J.P., Cevik, N., Murphy, M.L. | Cancer Chemother Rep. 1966 Jul; 50(5):287-91. |
| 12 | The Cure of Childhood Leukemia, into the age of miracles | John Laszlo | 1996, Rutgers University Press |
| 13 | Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey, and Man | Freireich E J, Gehan E A, Rail D P. Schmidt L H & Skipper H E. | Cancer Chemother. Rep. 50:219-44, 1966. |
| 14 | Advanced Preclinical and Clinical Trials of Natural Products and Related Compounds from Marine Sources. | Newman D.J., Cragg G. M. | Current Medicinal Chemistry, July 2004, vol. 11, no. 13. pp. 1693-1713 (21). |
| 15 | Marine Pharmacology in 1998: Antitumor and Cytotoxic Compounds | Alejandro M. S. Mayer | The Pharmacologist, Vol. 41, No. 4, 1999, p. 159 |
| 16 | Nature’s pharma sea | Modern Drug Discovery, on the web, ACS Publications | MDD lab, Jan. 2002, vol. 5, no. 1, pp. 32-38. |
| 17 | Natural Product-Based Anti-HIV Drug Discovery and Development Facilitated by the NCI Developmental Therapeutics Program | Stringner S. Yang, Gordon M. Cragg. David J. Newman, and John P. Bader | Journal of Natural Products, 200, vol. 64, no. 2 |
| 18 | Marine organisms as a source of new anticancer agents. | Gilberto Schwartsmann, Adriana Brondani da Rocha, Roberto GS Berlinck and Jose Jimeno | Lancet Oncol 2001; 2: 221-5 |
| 19 | Oceans: Medicine Chests of the Future? | A.J.S. Ray. Online on TheScientist.com (but only by subscription) | The Scientist 13 [19]1, Sep. 27, 1999 |
| 20 | Drugs and Cosmetics from the Sea | Anake Kijjoa and Pichan Sawangwong Marine drugs review article on the web | Mar. Drugs 2004, 2 |
| 21 | Compound 506U78 (2-amino-6-methoxypurinearabinoside) is active against resistant T-cell malignancy: preliminary results of an ongoing phase I trial. | Kurtzberg J, Keating MJ, Plunkett W, et al | Proc Am Soc Clin Oncol 15:A108, 1996 and J Clin Oncol 14:A1750, 1996 |
| 22 | Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. | Rodirguez, Carlos O., Christine M. Stellrecht, and Varsha Gandhi. | Blood, 1 Sept. 2003, Vol. 102, No. 5. pp. 1842-1848. |
| 23 | Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. | Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. | J Clin Oncol. 2000 Mar;18(5):995-1003 |
| 24 | Arabinosylguanine-induced Apoptosis of T-Lymphoblastic Cells: Incorporation into DNA Is a Necessary Step. | Carlos O. Rodigguez, Jr. and Varsha Ghandhi | Cancer Research 59, 4937-4943, October 1, 1999. |
| 25 | Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias | Stefan Faderl, Varsha Gandhi, Susan O'Brien, Peter Bonate, Jorge Cortes, Elihu Estey, Miloslav Beran, William Wierda, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Francis J. Giles, Min Du, Monica Kwari, Michael Keating, William Plunkett, and Hagop Kantarjian | Blood, 1 February 2005, Vol. 105, No. 3, pp. 940-947 |
| 26 | Phase I study of clofarabine plus idarubicin and clofarabine plus idarubicin plus cytarabine in patients with relapsed and primary refractory acute myeloid leukemia, myelodysplastic syndrome, and myeloid blast phase of chronic myeloid leukemia. | Faderl S, Ferrajolil A, Wierda W, et al. | Blood. 2004;104:501a. Abstract 1809. |
| 27 | Phase II trials of clofarabine in relapsed or refractory pediatric leukemia. | Jeha S, Razzouk BI, Rytting ME, et al. | Blood. 2004;104:196a. Abstract 684. |
| 28 | Complete Remission Following Clofarabine Treatment in Refractory Juvenile Myelomonocytic Leukemia. | Corey, Seth J MD, MPH; Elopre, Marily RN; Weitman, Steve MD, PhD; Rytting, Michael E MD; Robinson, Lisa J MD; Rumelhart, Stephen PA [S]; Goldman, Frederick D MD | Journal of Pediatric Hematology/Oncology. 27(3):166-168, March 2005. |
| Under the sea An abundance of potential anti-cancer drugs are waiting to be discovered in the ocean. |
Tammy Dotts | HemOnc Today, July 2004 |